LELegend Biotech LEGN NASDAQ · Zdravstvo · Združene države Amerike
$15.99 -8.63% -$1.51
- Market cap
- $2.96B
- Enterprise value
- $2.66B
- P/E
- -
- Forward P/E
- 142.1x
- PEG
- -
- P/S
- 2.2x
- P/FCF
- -
- EV/EBITDA
- 26.8x
- ROIC
- -0.0%
- Bruto marža
- 57.0%
- Neto marža
- -0.0%
- Dividend yield
- -
- Payout ratio
- -
- Neto dolg/EBITDA
- -2.9x
- Beta
- 0.40
- Free float
- 96.3%
O podjetju
Legend Biotech Corporation (LEGN) is a global biotechnology company focused on developing and commercializing innovative therapeutic products in the field of hematology and oncology. The company is dedicated to researching new therapies for patients with leukemia and lymphoma, and its portfolio includes several potential drugs that have undergone clinical trials. Legend Biotech prioritizes high-quality research and development, collaborates with academic institutions and pharmaceutical partners, and stays abreast of the latest innovations in oncology. With increasing awareness of hematological disorders and a growing interest in new treatment modalities, investing in Legend Biotech Corporation (LEGN) shares may represent an interesting opportunity for investors interested in the biotechnology sector and seeking a company focused on innovative therapeutic products.
Sector
Healthcare
Industry
Biotechnology
CEO
Alan S. Bash
Employees
3,300
Headquarters
Somerset
Vrednotenje
Je današnja cena primerna?
- Kaj govori v prid: Cena delnice je pod Bulios Fair Price.
Rast in ocene
Ali podjetje raste in kaj sledi?
- Kaj govori v prid: Prihodki so v zadnjih 3 letih rasli za 106 % letno.
- Kaj govori v prid: Analitiki v tem poslovnem letu pričakujejo rast prihodkov za 39 %.
- Na kaj bodite pozorni: Dobiček na delnico iz leta v leto močno niha.
Donosnost in kakovost
Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?
- Na kaj bodite pozorni: Podjetje je v zadnjih 12 mesecih poslovalo z izgubo.
Finančno zdravje
Ali zmore svoj dolg?
- Kaj govori v prid: Ima več denarja kot dolga: $460,7M proti $167,4M.
Kapital in dividende
Kaj podjetje počne z zasluženim denarjem?
Analitiki
Kaj menijo strokovnjaki in ali se to spreminja?
Lastniki in insajderji
Kdo ima delnice in kaj počne vodstvo?
Segmenti
Kateri del podjetja raste?
Primerjava s konkurenco
Kako se primerja s podobnimi podjetji?
Cena in tveganje
Kako se delnica obnaša?
Izkazi
Vse številke